Replacement of normal iron levels in pregnant women with acetyl aspartic protein iron administration

Aim During pregnancy, some blood changes are made normally for the normal development of the fetus and for the mother’s preparation for childbirth. A non-invasive clinical trial evaluated the efficacy and safety of an oral iron acetyl aspartic protein formulation for the treatment of anemia in pregnant women.

Material and methods In the period from 01.02.2015 to 31.12.2019 were included in this study 188 pregnant women who were separated in two groups. In Group A which included 98 pregnant women was administered Iron protein acetyl aspartilate plus Calcium folinate pentahydrate, while in group B control group included 90 pregnant women taking other various iron supplements.

Inclusions criteria ​ Age ≥18 years

Completion of the 12th week of pregnancy

Hemoglobin levels ≤ 10.5 g / dl,Hematocrit <32%

Exclusions criteria Age <18 years, Pregnancy stage less than 12 weeks

Co-administration of iron preparations parenterally

History of allergy to iron supplements, liver cirrhosis, acquired or chronic hemochromatosis

Aplastic, hemolytic and anemia of chronic diseases Underlying kidney Hypothyroidism or hyperthyroidism

The examinations that took place in the second, third trimester of pregnancy and in the period of childbirth were the following:

Laboratory blood analysis, urine analysis, electrolyte levels, thyroid hormones

Results According to our results, no statistically significant difference was found between the two groups of pregnant women.

Conclusion The symptoms range from mild to grave and if they left unattended can have serious adverse effects on both mother and fetus. Special attention must be given to nutrition during pregnancy.

Publication History

Article published online:
11 October 2022